title: The Innovative Medicines Initiative moves translational immunology forward.
abstract: The Innovative Medicines Initiative (IMI) was established in 2008 as a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre-competitive research. Several consortia supported by IMI are dedicated to immuno-inflammatory disorders, immune-based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.
authors.affiliation: Innovative Medicines Initiative, TO 56, Office 6/4 B-1049 Brussels, Belgium. michel.goldman@imi.europa.eu
authors.forename: Michel
authors.initials: M
authors.lastname: Goldman
authors.forename: Angela
authors.initials: A
authors.lastname: Wittelsberger
authors.forename: Maria-Teresa
authors.initials: MT
authors.lastname: De Magistris
mesh_terms: D000486:Allergy and Immunology; D000818:Animals; D003299:Cooperative Behavior; D004345:Drug Industry; D006801:Humans; D055818:Public-Private Sector Partnerships; D057170:Translational Research, Biomedical